Showing results (281-290 of 315) with videos related to

Sort By:
Pageof 32
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trialE Pujade-Lauraine, F Selle, G Scambia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocolE Bernichon, A Vallard, Q Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 6, 2018
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II studyS Banerjee, A M Oza, M J Birrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2021
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trialA Le Cesne, J-Y Blay, D Cupissol, et al.
Scientific Reports|July 27, 2024
MASLD does not affect fertility and senolytics fail to prevent MASLD progression in male miceJessica D Hense, Driele N Garcia, Bianka M Zanini, et al.
Gynecologic Oncology|April 8, 2022
Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG)S Henno, C Jeanne, T De La Motte Rouge, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2015
ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patientsO Trédan, C Ménétrier-Caux, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2005
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMOJ-Y Blay, S Bonvalot, P Casali, et al.
ESMO Open|May 20, 2025
HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparibL Beltrame, L Mannarino, A Sergi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2024
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapseJ-Y Blay, C Schiffler, O Bouché, et al.
Pageof 32